PEN HAS GLUE

Dispositif en forme de tige, applicateur de colle comportant une unité d'entraînement (12) et un logement (16) recevant une cartouche de colle (18). L'unité d'entrainement (12) et le logement (16) sont alignés.

HINGE OF CONTAINER

ROLLER OF BELT FOR a Safety belt Of a VEHICLE

LINEARE IONENVERARBEITUNGSVORRICHTUNG MIT EINER VERBESSERTEN MECHANISCHEN ISOLATION UND ANORDNUNG

Eine Ionenverarbeitungsvorrichtung umfasst eine Mehrzahl von Elektroden, einen ersten und zweiten Isolator, ein Gehäuse und eine Mehrzahl von elastischen ersten Trägern und zweiten Trägern. Jede Elektrode weist eine Länge entlang einer Mittelachse auf und umfasst eine erste Endregion und eine axial gegenüberliegende zweite Endregion. Der erste und zweite Isolator sind koaxial um die erste bzw. zweite Endregion angeordnet. Das Gehäuse ist koaxial um die Elektroden, den ersten Isolator und den zweiten Isolator angeordnet. Die ersten Träger erstrecken sich zwischen und in Kontakt mit dem ersten Isolator und dem Gehäuse. Die zweiten Träger erstrecken sich zwischen und in Kontakt mit dem zweiten Isolator und dem Gehäuse. Die Träger isolieren die Elektroden von externen Kräften.

ELECTROLYTIC SYSTEM AND METHOD FOR FILTERING AN AQUEOUS PARTICULATE SUSPENSION

An electrolytic filtration method and apparatus for the concentration and collection of suspended particulates from aqueous solutions is disclosed. The electrolytic cell contains at least an anode and a cathode, and in one embodiment contains a plurality of anodes and cathodes. The electrolytic cell also contains a filter, and in one embodiment the filter is a moving belt filter. While not bound by theory, the electrolytic filtration method and apparatus is based on the electrophoretic movement of algae particles suspended in an aqueous solution away from the filter under the influence of an electric field. In one embodiment the electric field is a pulsed waveform with unidirectional voltage or current pulses. In another embodiment, the electric field is a pulsed waveform with bidirectional voltage or current pulses. 1. A method for the filtration of suspended particles in a solution comprising:a. adding a solution with suspended particles to an electrolytic cell containing a filter and at least an anode and a cathode;b. establishing a predetermined gap between said anode and said cathode;c. connecting said anode and said cathode to a power supply; andd. delivering an electric field from said power supply to said anode and said cathode; wherein said suspended particles move away from said filter, creating a zone of depleted suspended particles near the filter.2. The method of wherein said suspended particles are algae particles.3. The method of wherein said anode and said cathode are high overvoltage electrodes.4. The method of wherein said suspended particles are concentrated and collected from the surface region of the electrolytic cell claim 2 , and transferred to a collection vessel.5. The method of wherein said suspended particles are concentrated and collected from the surface region of the electrolytic cell claim 2 , and transferred to a moving filter belt.6. The method of wherein said anode is positioned on one side of said filter and said cathode is ...

ELECTROLYTIC SYSTEM AND METHOD FOR CONCENTRATING AN AQUEOUS PARTICULATE SUSPENSON

An electrolytic method and apparatus for the concentration and collection of suspended particulates from solutions is disclosed. In one embodiment, the solution is an aqueous solution and the suspended particles are algae particles. The electrolytic cell contains at least an anode and a cathode, and in one embodiment contains a plurality of anodes and cathodes. While not bound by theory, the electrolytic method and apparatus is based on the electrophoretic movement of algae particles suspended in an aqueous solution under the influence of an electric field. In one embodiment the electric field is a pulsed wavefrom with unidirectional voltage or current pulses. In another embodiment, the electric field is a pulsed waveform with bidirectional voltage or current pulses. 1. A method for the concentration of an aqueous suspension , the method comprising:a. adding an aqueous particulate solution to an electrolytic cell containing at least an anode and a cathode;b. establishing a predetermined gap between said anode and said cathode;c. connecting said anode and said cathode to a power supply;d. delivering an electric field from said power supply to said anode and said cathode; ande. collecting the suspended particles from a region of said electrolytic cell wherein the suspended particles are concentrated.2. The method of wherein said suspended particles are algae particles.3. The method of wherein said anode and said cathode are high overvoltage electrodes.4. The method of wherein the electrolytic cell has a surface region and said suspended particles are concentrated and collected from the surface region of the electrolytic cell.5. The method of wherein the electrolytic cell has a bottom region and said suspended particles are concentrated and collected from the bottom region of the electrolytic cell.6. The method of wherein the electrolytic cell has a cathode region and said suspended particles are concentrated and collected from the cathode region of the electrolytic ...

Tusc2 therapies

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods. 148-. (canceled)49. A method of determining the EMT status of tumor cells , comprising:measuring in a sample of the tumor cells the relative expression level of each gene of an EMT gene signature (EMTGS), wherein the EMTGS consists essentially of the following genes:SERPINA3, ACTN1, AGR2, AKAP12, ALCAM, AP1M2, AXL, BSPRY, CCL2, CDH1, CDH2, CEP170, CLDN3, CLDN4, CNN3, CYP4X1, DNMT3A, DSG3, DSP, EFNB2, EHF, ELF3, ELF5, ERBB3, ETV5, FLRT3, FOSB, FOSL1, FOXC1, FXYD5, GPD1L, HMGA1, HMGA2, HOPX, IFI16, IGFBP2, IHH, IKBIP, IL-11, IL-18, IL6, IL8, ITGA5, ITGB3, LAMB1, LCN2, MAP7, MB, MMP7, MMP9, MPZL2, MSLN, MTA3, MTSS1, OCLN, PCOLCE2, PECAM1, PLAUR, PLXNB1, PPL, PPP1R9A, RASSF8, SCNN1A, SERPINB2, SERPINE1, SFRP1, SH3YL1, SLC27A2, SMAD7, SNAIL SNAI2, SPARC, SPDEF, SRPX, STAT5A, TBX2, TJP3, TMEM125, TMEM45B, TWIST1, VCAN, VIM, VWF, XBP1, YBX1, ZBTB10, ZEB1, ZEB2;calculating an EMTGS index score for said tumor cells by applying an algorithm to the measured expression level values that incorporates the contributions of co-correlated genes; anddetermining if said EMTGS index score is more similar to an EMTGS index score from a reference epithelial tumor cell or an EMTGS index score from a reference mesenchymal-like tumor cell, and thus determining the EMT status of the sample tumor cells.50. The method of claim 49 , wherein the tumor cells are NSCL cancer claim 49 , breast cancer claim 49 , colorectal cancer claim 49 , or pancreatic cancer tumor cells.51. A method of identifying a human tumor as likely to be responsive or non-responsive to treatment with an EGFR kinase inhibitor claim 49 , comprising:measuring in a ...

METHOD FOR LABELING NANOCLAY FOR TRACKING THEM WITHIN DIFFERENT SOLID AND LIQUID MATERIAL

A method of monitoring a location of a nanoparticle within a material is described herein. The method includes the steps of providing at least one nanoclay particle, attaching a fluorescent tag to the at least one nanoclay particle, and determining a fluorescence of the fluorescent-labeled nanoclay particle. The method also includes forming the material including the at least one fluorescent-labeled nanoclay particle, depositing the material in an aqueous solution, and detecting a movement of the fluorescent-labeled nanoclay particle from the material to the aqueous solution. 1. A method of monitoring a location of a nanoparticle within a material , including the steps of:providing at least one nanoclay particle;attaching a fluorescent tag to the at least one nanoclay particle to form a fluorescent-labeled nanoclay particle;determining a fluorescence of the fluorescent-labeled nanoclay particle;inserting the fluorescent-labeled nanoclay particle into the material;depositing the material in an aqueous solution; anddetecting a movement of the fluorescent-labeled nanoclay particle from the material to the aqueous solution.2. A method in accordance with claim 1 , wherein the material is one of a polymeric material and a biological material.3. A method in accordance with claim 1 , including the step of:removing the material from the aqueous solution; anddetecting the presence of the at least one fluorescent-labeled nanoclay particle in the aqueous solution.4. A method in accordance with claim 1 , wherein the fluorescent tag is selected from a group consisting of fluorescein and rhodamine.5. A method in accordance with claim 4 , wherein the fluorescent tag is attached to the nanoclay particle with a covalent bond.6. A method in accordance with claim 1 , including the steps of:providing a nanoclay platelet;reacting the nanoclay platelet with a mercaptosilane to produce a mercaptosilane modified nanoclay particle including thiol moieties; andreacting the mercaptosilane ...

METHODS FOR TREATMENT OF PEDIATRIC SYSTEMIC MASTOCYTOSIS

Methods for treating pediatric patients with systemic mastocytosis are described by administering midostaurin. 1. A method for treating systemic mastocytosis in a pediatric subject in need thereof , comprising administering to the subject an effective dosing regimen comprising midostaurin.2. The method of wherein the pediatric subject is an infant.3. The method of wherein the mastocytosis is congenital or prenatal.4. The method of wherein the mastocytosis comprises the Kit D816V mutation.5. The method of wherein the mastocytosis is indolent.6. The method of wherein the mastocytosis is cutaneous mastocytosis.7. The method of wherein the systemic mastocytosis is indolent systemic mastocytosis claim 1 , smoldering systemic mastocytosis claim 1 , systemic mastocytosis with associated hematological neoplasm claim 1 , aggressive systemic mastocytosis or mast cell leukemia.8. The method of wherein the mastocytosis is not responsive to standard of care therapy.9. The method of wherein standard of care comprises antihistamines claim 4 , cromolyn claim 4 , montelukast claim 4 , antibiotics or corticosteroids claim 4 , or any combination thereof.10. The method of wherein the midostaurin is administered twice daily at a dose of 30 mg/m claim 1 , 45 mg/mor 60 mg/m claim 1 , or any combination or regimen thereof.11. The method of wherein the midostaurin is administered orally.12. The method of wherein the midostaurin is administered as a liquid formulation.13. The method of wherein ondansetron was administered prophylactically with each dose of midostaurin.14. The method of wherein the midostaurin administration reduces bullae claim 1 , reduces skin blistering claim 1 , reduces skin flushing claim 1 , reduces serum tryptase levels claim 1 , or any combination thereof.15. The method of wherein administration of midostaurin is discontinued when clinical improvement occurs.16. The method of wherein administration of midostaurin is discontinued when clinical improvement of systemic ...

METHODS AND AGENTS FOR TREATING INFECTIONS

Methods are described for treating systemic fungal and mycobacterial infections by treatment to enhances a Th1 response, reduces a Th2 response, or the combination thereof. Agents that antagonize the IL-4, the IL-13 receptor, or the combination thereof achieve the desired results. 1. A method for treating a fungal , mycobacterial or viral infection in a subject in need thereof , comprising administering to the subject an agent that enhances a Th1 response , reduces a Th2 response , or the combination thereof.2. The method of wherein the fungal infection is disseminated or systemic.3Coccidioides, Candida, Blastomyces, Histoplasma, Pneumocystis, Paracoccidioides, Talaromyces, Aspergillus, CryptococcusMucorales.. The method of wherein the fungal infection is caused by claim 1 , or4. The method of wherein the systemic fungal infection is coccidioidomycosis.5. The method of wherein the mycobacterial infection is tuberculosis.6. The method of wherein the subject is a pediatric subject.7. The method of wherein the subject is immunocompromised or has an immunodeficiency disease.8. The method of wherein the agent blocks IL-4 signaling claim 1 , IL-13 signaling claim 1 , or the combination thereof.9. The method of wherein the agent is an IL-4 receptor antagonist.10. The method of wherein the agent is an IL-4 receptor alpha antagonist.11. The method of wherein the agent is an IL-13 receptor antagonist.12. The method of wherein the agent is an IL-13 receptor alpha1 antagonist.13. The method of wherein the agent is an antibody or fragment thereof.14. The method of wherein the antibody or fragment thereof is a monoclonal antibody or fragment thereof.15. The method of wherein the agent is dupilumab claim 13 , pascolizumab claim 13 , lebrikizumab claim 13 , anrukinzumab claim 13 , or tralokinumab.16. The method of wherein the agent is pitrakinra.17. The method of wherein the subject is also administered interferon-gamma.18. A method for determining whether subject is a candidate ...

SYSTEM LINE

System line includes at least: 1100. Conveying system () comprising:{'b': 2', '3, 'at least one supporting frame (, ) extending substantially in parallel with the feeding direction (F) of the system;'}{'b': 2', '3, 'at least one plurality of driving means supported by said supporting frames (, );'}{'b': '9', 'at least one motor () or at least a pneumatic device for driving at least one portion of said plurality of driving elements;'}at least one drive assembly to transfer the motion from said motor to said at least one portion of the plurality of driving elements;at least one control and power ASi system;{'b': '12', 'at least one main ASi-controller ();'}{'b': 11', '12', '11', '35, 'at least one secondary ASi-controller (); said main ASi-controller () communicating with said at least one secondary ASi-controller () or with other ASi-main controllers through at least one ASi-interface cable ();'}{'b': 12', '13, 'said main Asi-controller () comprising a main Asi-box (); and'}{'b': 11', '14, 'said secondary Asi-controller () comprising a secondary Asi-box ();'}{'b': 13', '14, 'said main () and secondary () ASi-boxes having at least one first corresponding transversal coupling dimension (M);'}{'b': 2', '3', '17', '13', '14, 'said supporting frame (,) comprising a housing compartment () extending in the feeding direction of the system line, adapted to house said main () and secondary () ASi-boxes;'}{'b': 2', '3', '13', '14', '17, 'said supporting frame (, ) comprising fastening means to removably block said at least one main box () and said at least one secondary box () inside the housing compartment ();'}{'b': 17', '34', '35, 'said housing compartment () comprising at least one housing seat () for said at least one ASi-interface cable ();'}{'b': 34', '35', '13', '14', '7', '13', '14', '12', '11', '35, 'said housing seat () is shaped so as to arrange the ASi-interface cable () in such a position, with respect to said main () and secondary () boxes, that it is penetrated ...

Anti-gdf15 antibodies

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Surface cross-linked lipidic particles, methods of production and uses therefor

A method for producing a composition of lipidic particles coated with a cross-linked surface mesh, the method comprising the steps of: (i) preparing lipidic particles comprising pharmaceutically acceptable lipids, (ii) binding hydrophilic polymer chains to the surface of the lipidic particles, and (iii) cross-linking the hydrophilic polymer chains to form the cross-linked surface mesh. Pharmaceutical compositions comprising surface modified lipidic particles prepared according to this method are also described. The lipidic particles resist fusion with red blood cells and platelets in vitro, and are amenable to further derivatization by targeting molecules for controlled release of component and contents, thus providing a new generation of drug carrier systems.

SYNTHETIC PLATELETS

A synthetic platelet substitute that interacts with platelets and the (sub)endothelium, comprising: (a) a carrier molecule comprising lipidic particles with a cross-linked surface mesh, the lipidic particles comprising: an inner lipidic particle of pharmaceutically acceptable particle-forming lipids; hydrophilic polymer chains linked to the surface of the lipidic particle, the hydrophilic polymer chains comprising a crosslinkable end group at free ends thereof; and cross-linker groups linking the end groups of the hydrophilic polymer chains to form the cross-linked surface mesh; and (b) at least one receptor molecule attached to the surface of the carrier molecule. The receptor molecule can be a peptide moiety specific for ligands involved in platelet function. 121.-. (canceled)22. A synthetic platelet substitute that interacts with platelets and a subendothelium , comprising:a. a carrier molecule comprising lipidic particles with a cross-linked surface mesh, the lipidic particles comprising: an inner lipidic particle of pharmaceutically acceptable particle-forming lipids; hydrophilic polymer chains linked to the surface of the lipidic particle, the hydrophilic polymer chains being straight chain non-toxic and comprising a crosslinkable end-group at free ends thereof; and cross-linker groups linking the end groups of the hydrophilic polymer straight chains to form the cross-linked surface mesh; andb. at least one receptor molecule attached to the surface of the carrier molecule, wherein the receptor molecule is selected from the group consisting of a peptide consisting of SEQ ID NO: 3, an analog thereof consisting of one amino acid change from the sequence of SEQ ID NO: 3, and a modification of said peptide or said analog, wherein said modification is selected from the group consisting of one or more of an insertion of a Cys residue, a spectrophotometrically traceable amino acid and a poly-Gly tag consisting of 1 to 5 Gly residues.23. The synthetic platelet ...

Miter Saw

The miter saw includes a base assembly, a rotatable table rotatably connected to the base assembly and having a plane, a saw assembly including a motor and a blade disposed on an arbor, and a pivot arm pivotally attached to the table and supporting the saw assembly. The motor preferably drives a belt, which drives a first gear. The first gear meshes with an idler gear, which in turn meshes with a gear disposed on the arbor. 124-. (canceled)25. A miter saw comprising:a base assembly;a rotatable table rotatably connected to the base assembly and having a table plane;a fence assembly connected to the base assembly and having an uppermost point, a front face defining at least part of a fence plane, and a rear portion behind the front face;a saw assembly pivotable about a chopping axis between an upper non-cutting position and a lowered cutting position, the saw assembly including a motor with a motor shaft having an axis, a blade having a radius and being disposed on an arbor, the arbor having an axis and a first portion carrying the blade, the motor driving the arbor via at least one intervening component, the intervening component having a rotational axis;a pivot arm pivotally attached to the table and supporting the saw assembly, the pivot arm and saw assembly being pivotable about a horizontal bevel axis from a first position where the blade is substantially perpendicular to the table to a second position where the blade is disposed at an angle relative to the table, the angle between the blade and the table being about 45 degrees,wherein the axes of the motor shaft, the arbor and the intervening component form a triangle, where the axis of the arbor is below the uppermost point of the fence assembly when the saw assembly is in the lowered cutting position, the axes of the motor shaft and the intervening component are above the uppermost point of the fence assembly when the saw assembly is in the lowered cutting position, the axis of the motor shaft is behind the ...

MRI STREAK-ARTIFACT SUPPRESSION, SYSTEM AND METHOD

A method for producing a streak-suppressed magnetic resonance (MR) image of a subject includes generating an interference covariance matrix {circumflex over ( )}R front N coil images Ij (x,y), j={1, 2, . . . , N}, each of the N coil images Ij (x,y) corresponding to MR signals detected by a respective one of a phased array of N coils of an MRI scanner. The MR signals originate in voxels of the subject corresponding to an artifact-corrupted region of a coil image. Coordinates (x,y) correspond to a location within a cross-sectional plane of the subject. The method also includes, for subject-regions of cross-sectional plane centered at a respective location (x,y), determining a coil weight vector W (x,y) from {circumflex over ( )}R. The method also includes generating the streak-suppressed MR image as a weighted sum of the coil images Ij (x,y), each weight of the weighted sum being Wj* (x,y), a jelement of a complex conjugate of coil weight vector W (x,y). 1. A method for producing a streak-suppressed magnetic resonance (MR) image of a subject comprising:{'sub': j', 'j, 'generating an interference covariance matrix {circumflex over (R)} from N coil images I(x,y), j={1, 2, . . . , N}, each of the N coil images I(x,y) corresponding to MR signals detected by a respective one of a phased array of N coils of an MRI scanner, the MR signals originating in a first plurality of voxels of the subject corresponding to artifact-region of a coil image corrupted by an artifact, coordinates (x,y) corresponding to a location within a cross-sectional plane of the subject;'}{'o': {'@ostyle': 'single', 'W'}, 'for each of a plurality of subject-regions of cross-sectional plane centered at a respective location (x,y), determining a coil weight vector (x,y) from the interference covariance matrix {circumflex over (R)}; and'}{'sub': j', 'j, 'sup': 'th', 'o': {'@ostyle': 'single', 'W'}, 'generating the streak-suppressed MR image as a weighted sum of the N coil images I(x,y), each weight of the ...

HIGH CONCENTRATION CELL PENETRATING CASPASE INHIBITOR CONJUGATES, COMPOSITIONS AND METHODS THEREOF

A method of providing a high concentration disulfide-linked caspase inhibitor-cell penetrating peptide conjugate is described. The method includes incubating a caspase inhibitor having one or more thiol groups with a reducing agent selected from dithiothreitol (DTT), 2-mercaptoethanol (2-ME) and tris(2-carboxyethyl)phosphine (TCEP) to provide a reduced caspase inhibitor, removing the reducing agent from the reduced caspase inhibitor, and conjugating the reduced caspase inhibitor with a cell-penetrating peptide by a disulfide linkage. 1. A method of providing a disulfide-linked caspase inhibitor-cell penetrating peptide conjugate , comprising:incubating a caspase inhibitor having one or more thiol groups with a reducing agent selected from dithiothreitol (DTT), 2-mercaptoethanol (2-ME) and tris(2-carboxyethyl)phosphine (TCEP) to provide a reduced caspase inhibitor;removing the reducing agent from the reduced caspase inhibitor; andconjugating the reduced caspase inhibitor with a cell-penetrating peptide by a disulfide linkage.2. The method of claim 1 , wherein the caspase inhibitor is selected from the group consisting of a caspase -1 claim 1 , -2 claim 1 , -3 claim 1 , -4 claim 1 , -5 claim 1 , -6 claim 1 , -7 claim 1 , -8 claim 1 , -9 claim 1 , -10 claim 1 , -11 claim 1 , -12 claim 1 , and -14 inhibitor.3. The method of claim 1 , wherein the caspase inhibitor is selected from a XBIR3 claim 1 , a XBIR2 claim 1 , a linker-BIR2 and a dominant-negative caspase 6.4. The method of claim 1 , wherein the removing the reducing agent is by filtration.5. The method of claim 1 , further comprising a buffer exchange wherein the reduced caspase inhibitor is comprised in a pharmaceutically acceptable excipient.6. The method of claim 1 , wherein the cell-penetrating peptide is selected from Penetratin1 claim 1 , transportan claim 1 , pIsl claim 1 , TAT(48-60) claim 1 , pVEC claim 1 , MTS claim 1 , MAP claim 1 , polyarginines claim 1 , DPV1047 claim 1 , M918 claim 1 , M1073 claim 1 ...

Masp-2 inhibitors and methods of use

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

ANTI-GDF15 ANTIBODIES

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15. 161-. (canceled)62. An isolated antibody that binds human GDF15 , comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:(a) an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:250 (Hu01G06 IGHV1-69 F1), and an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:92 (Hu01G06 IGKV1-39 F1); and(b) an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:248 (Hu01G06 IGHV1-18 F2), and an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:254 (Hu01G06 IGKV1-39 F2).63. The antibody of claim 62 , wherein the antibody comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:(a) an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:250 (Hu01G06 IGHV1-69 F1), and an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:92 (Hu01G06 IGKV1-39 F1); and(b) an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:248 (Hu01G06 IGHV1-18 F2), and an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:254 (Hu01G06 IGKV1-39 F2).64. The antibody of claim 62 , wherein the antibody comprises an immunoglobulin heavy chain variable region and an immunoglobulin light ...

UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY

This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed. A representative halonium compound of the disclosure is: 1122-. (canceled)124. A process for cyclizing an alkene or halogenating an aromatic ring comprising contacting the alkene or aromatic ring with the compound of under conditions permitting cyclization of the alkene or halogenation of the aromatic ring.125. The process of claim 124 , wherein the alkene is a polyene claim 124 , alkenoic acid or alkenyl alkyl ether.126. The process of claim 124 , wherein the cyclization is a ring-forming halolactonization or ring-expanding bromoetherification.127. The process of claim 124 , wherein the halogenation is a mono-halogenation and the aromatic ring is a substituted phenyl. This application claims priority of U.S. Provisional Application No. 61/403,406, filed Sep. 14, 2010, the contents of which are hereby incorporated by reference.The work disclosed herein was made with government support under Grant No. CHE0844593 from the National Science Foundation and Grant No. GM-084994 from the National Institutes of Health. Accordingly, the U.S. Government has certain rights in this invention.Throughout this application, certain publications are referenced in parentheses. Full citations for these publications may be found immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention relates.With little question, the ability to convert polyene starting materials into far more complex frameworks via stereoselective cation-π cyclizations constitutes one of the most ...

Method and apparatus for charging an energy store

An energy store ( 14 a ) has at least three energy storage sections (u, v, w) and at least two switching elements. Each energy storage sections (u, v, w) has multiple energy storage modules and each energy storage module has at least one energy storage element that receives and stores energy from an energy source ( 12 ). The energy store ( 14 a ) is connected to a first coil ( 50 ) so that a voltage induced in the first coil ( 50 ) is used to charge the energy storage elements. The energy store ( 14 a ) is matched to properties of the voltage provided by the first coil ( 50 ) by switching the switching elements. As a result, the energy storage modules of an energy storage section (u, v, w) are connected in parallel and/or in series with one another and/or at least one energy storage module of at least one energy storage section (u, v, w) is bypassed.

ROLLER -WAY CONVEYOR

A conveying system includes: two axially spaced supporting tubular frames extending substantially parallel in the conveying direction (F) of the conveying system; at least one plurality of driving rollers and/or wheels; at least one plurality of supporting shafts, each adapted to be engaged in at least one of the supporting tubular frames to support at least one driving roller and/or at least one driving wheel; at least one first supporting bearing () for each supporting shaft. The conveying system () further includes at least one housing () for the at least one first supporting bearing (). The housing includes fastening elements () to removably fasten the housing () and bearing () held therein within at least one supporting tubular frame. 1100. Conveying system () comprising:{'b': 2', '3, 'two axially spaced supporting tubular frames (, ) extending substantially'}parallel in the conveying direction (F) of the conveying system;{'b': 4', '5, 'at least one plurality of driven rollers () and/or wheels () ;'}{'b': '6', 'at least one plurality of supporting shafts (), each adapted to be engaged in'}{'b': 2', '3, 'at least one of said supporting tubular frames (, ) to support at least one driving roller'}{'b': 4', '5, '() and/or at least one driving wheel ();'}{'b': 7', '6, 'at least one first supporting bearing () for each supporting shaft ();'}{'b': '8', 'characterized by comprising at least one housing () for said at least one first'}{'b': '7', 'supporting bearing ();'}{'b': '9', 'said housing comprising fastening means () to removably fasten said housing'}{'b': 8', '7', '2', '3, '() and bearing () held therein within at least one supporting tubular frame (, );'}{'b': '9', 'said fastening means () comprise anchoring means adapted to removably'}{'b': 13', '22', '2', '3, 'engage in ribs () obtained on inner side walls () of said tubular frames (, ).'}{'b': 13', '2', '3, 'said ribs () axially extend inward the supporting tubular frame (, ) and have'}a portion provided ...

TAGGING DIGITAL CONTENT WITH QUERIES

Digital content can be annotated with a query. Upon selection of the query, a search can be initiated on a search engine with the query and search results relevant to the query are returned. Suggestions can be provided automatically in conjunction with query insertion. Suggestions can be supplied as a function of an input fragment and past search engine queries, among other things. 1. A computer-implemented method , comprising:creating a hyperlink search query automatically in response to text input; andannotating a piece of digital content with the query.2. The method of further comprises suggesting a search term as the text input for the query as a function of past search-engine queries and an input query fragment.3. The method of further comprises:identifying an entity from the query;extracting one or more related entities from a knowledge repository; andsuggesting the search term as a function of the one or more related entities.4. The method of further comprises automatically detecting an object in the piece of digital content and suggesting the search term based on a class of object detected.5. The method of further comprises suggesting the search term as a function of social network service information.6. The method of further comprises:identifying an entity from the query;extracting one or more related entities from a knowledge repository; andadding one or more of the one or more related entities to the query.7. The method of further comprises displaying the one or more related entities with the query with respect to the piece of digital content.8. The method of further comprises:detecting an object automatically in the piece of digital content; andproviding the identity of the detected object as the text input.9. The method of further comprises recording information about a user that selects the query and initiates a search.10. The method of claim 1 , further comprises initiating a search on a search engine with the query in response to a signal indicative ...

SEARCH ANNOTATION AND SUGGESTION

Digital content can be annotated with a search annotation. A user can specify or otherwise identify one or more terms, comprising a query, in conjunction with an annotation signal, for example. Suggestions can be provided automatically to aid a user in specifying the terms, among other things. Furthermore, a hyperlink can be generated that targets a search engine with the query or some other resource. Subsequently, the one or more terms are replaced with the hyperlink. 1. A computer-implemented method , comprising:identifying a signal indicative of a desire to inject a hyperlink; andsuggesting one or more queries as a function of textual input following the signal.2. The method of further comprises suggesting the one or more queries as a function of one or more words that precede the signal.3. The method of further comprises receiving a selection of one of the one or more queries.4. The method of further comprises generating a hyperlink targeting a search engine with the one of the one or more queries.5. The method of further comprises replacing the one of the one or more queries with the hyperlink.6. The method of comprises identifying a question mark as the signal.7. The method of comprises identifying a question mark gesture as the signal.8. The method of further comprises presenting the one or more queries in a drop down list.9. The method of further comprises presenting the one or more queries in a distinct window panel.10. The method of further comprises suggesting one or more uniform resource identifiers identifying a web resource as a function of the textual input.11. A system claim 1 , comprising:a processor coupled to a memory, the processor configured to execute the following computer-executable components stored in the memory:a first component configured to identify an annotation signal in-line with text; anda second component configured to automatically suggest one or more queries comprising one or more search terms based on a query fragment following ...

DRUG DELIVERY SYSTEM AND METHOD FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASE

Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease. 1. As an article of manufacture , an effective amount of a Bryostatin in a biopolymer said biopolymer comprising a plurality of spheres in which said spheres have a diameter of one to 1000 nanometers , for the treatment of neuro-degenerative disease.2. The article of manufacture of wherein said a Bryostatin is selected from the group consisting of Bryostatins 1-20.3. The article of manufacture of wherein said biopolymer is resistant to acid.4. The article of manufacture of wherein said biopolymer is a poly (D claim 3 , L-lactide-coglycoside).5. The article of manufacture of wherein said poly (D claim 4 , L-lactide-co-glycoside) has a ratio of lactide and glycoside of 25-75% lactide.6. The article of manufacture of wherein said microspheres are lyophilized for reconstitution in an aqueous solution.7. The article of manufacture of wherein said microspheres are held in suspension for oral administration.8. The article of manufacture of wherein said microspheres are held in an oral dosage form selected from the group of tablets claim 1 , capsules claim 1 , gel caps claim 1 , and powders.9. A method of treating neuro-degenerative disease comprising the steps of administering an effective amount of a Bryostatin held in a plurality of microspheres claim 1 , each microsphere comprising a biopolymer and Bryostatin said microspheres having a diameter of one to 1000 nanometers.10. The method of wherein said Bryostatin is selected from the group consisting of Bryostatins 1-20.11. The method of wherein said biopolymer is resistant to acid.12. The method of wherein said biopolymer is a poly (D claim 11 , L-lactide-coglycoside).13. The method of wherein said poly (D claim 12 , L-lactide-co-glycoside) has a ratio of lactide and glycoside of 25-75% lactide.14. The method of wherein said microspheres are lyophilized for reconstitution in an ...

TUSC2 THERAPIES

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. 115-. (canceled)16. A method for treating a subject having a cancer , wherein it was determined that at least 10% of the cells of said cancer are apoptotic , the method comprising administering a TUSC2 therapy to the subject.17. The method of claim 16 , wherein the TUSC2 therapy comprises administration of a TUSC2 expression vector.18. The method of claim 17 , wherein the TUSC2 expression vector is plasmid DNA.19. The method of claim 18 , wherein the plasmid is pLJ143/KGB2/FUS1.20. The method of claim 17 , wherein the TUSC2 expression vector is provided in a liposome.21. The method of claim 20 , wherein the liposome is a DOTAP:cholesterol liposome.22. The method of claim 21 , wherein the DOTAP:cholesterol ratio is between about 1.5:1 and 1:1.5.23. (canceled)24. The method of claim 21 , wherein the TUSC2 expression vector and DOTAP:cholesterol liposome are administered in a dose of from about 0.01 mg/kg to about 0.10 mg/kg.2527-. (canceled)2827. The method of claim claim 21 , wherein the TUSC2 polypeptide is myristoylated.2927. The method of claim claim 21 , wherein the TUSC2 polypeptide is comprised in a nanoparticle.30. The method of claim 29 , wherein the nanoparticle is a lipid-based nanoparticle claim 29 , a superparamagnetic nanoparticle claim 29 , a nanoshell claim 29 , a semiconductor nanocrystal claim 29 , a quantum dot claim 29 , a polymer-based nanoparticle claim 29 , a silicon-based nanoparticle claim 29 , a silica-based nanoparticle claim ...

TUSC2 THERAPIES

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. 178-. (canceled)79. A method for treating a subject having a cancer , comprising administering to the subject an effective amount of a TUSC2 therapy , an epidermal growth factor receptor (EGFR) inhibitor and an anti-inflammatory agent to treat the cancer.80. The method of claim 79 , wherein the TUSC2 therapy is administered after the epidermal growth factor receptor (EGFR) inhibitor or the anti-inflammatory agent.81. The method of claim 79 , wherein the TUSC2 therapy is administered before or essentially simultaneously with the epidermal growth factor receptor (EGFR) inhibitor or the anti-inflammatory agent.82. The method of claim 79 , wherein the cancer was determined to express an EGFR.83. The method of claim 79 , wherein the TUSC2 therapy comprises administration of a TUSC2 expression vector.84. The method of claim 83 , wherein the TUSC2 expression vector is plasmid DNA.85. The method of claim 83 , wherein the TUSC2 expression vector is provided in a liposome.86. The method of claim 85 , wherein the liposome is a DOTAP:cholesterol liposome.87. The method of claim 79 , wherein the TUSC2 therapy comprises administration of a TUSC2 polypeptide.88. The method of claim 87 , wherein the TUSC2 polypeptide is myristoylated.89. The method of claim 87 , wherein the TUSC2 polypeptide is comprised in a nanoparticle.90. The method of claim 79 , wherein the EGFR inhibitor is a tyrosine kinase inhibitor.91. The method of claim 79 , wherein the EGFR inhibitor is ...

Compositions for delivering peptide yy and pyy agonists

The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.

TUSC2 THERAPIES

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. 1. A method for treating a subject having a cancer , comprising administering to the subject an effective amount of a TUSC2 therapy , an epidermal growth factor receptor (EGFR) inhibitor and an anti-inflammatory agent to treat the cancer.2. The method of claim 1 , wherein the TUSC2 therapy is administered after the epidermal growth factor receptor (EGFR) inhibitor or the anti-inflammatory agent.3. The method of claim 1 , wherein the TUSC2 therapy is administered before or essentially simultaneously with the epidermal growth factor receptor (EGFR) inhibitor or the anti-inflammatory agent.4. The method of claim 1 , wherein the cancer was determined to express an EGFR.5. The method of claim 1 , wherein the TUSC2 therapy comprises administration of a TUSC2 expression vector.6. The method of claim 5 , wherein the TUSC2 expression vector is plasmid DNA.7. The method of claim 5 , wherein the TUSC2 expression vector is provided in a liposome.8. The method of claim 7 , wherein the liposome is a DOTAP:cholesterol liposome.9. The method of claim 1 , wherein the TUSC2 therapy comprises administration of a TUSC2 polypeptide.10. The method of claim 9 , wherein the TUSC2 polypeptide is myristoylated.11. The method of claim 9 , wherein the TUSC2 polypeptide is comprised in a nanoparticle.12. The method of claim 1 , wherein the EGFR inhibitor is a tyrosine kinase inhibitor.13. The method of claim 1 , wherein the EGFR inhibitor is an EGFR binding antibody.14. The ...

SYSTEM AND METHODS FOR MEASURING PHYSIOLOGICAL PARAMETERS

The present invention relates generally to a system and methods for measuring physiological parameters. More specifically, the present invention relates to a noncontact technology by which one or more physiological parameters of a subject may be efficiently and quickly detected. Among other advantages, the present invention can be used to assess and monitor vital signs of one or more subjects in a variety of contexts including for medical or security triage purposes, for use in healthcare waiting rooms, as part of human imaging systems, or during surgery. 1. A system for determining one or more physiological parameters of a living subject comprising:a capture device configured to capture at least two images that have a temporally sequential relationship of a region of interest (ROI) on a body surface of the living subject and generate digital signals as digital output;a processing component by which the digital output is processed, whereby said component:(a) captures each of the at least two image as information on an analog-to-digital sensor that has been calibrated, based upon the one or more physiological parameters, environmental context in which the living subject is positioned, and specifications of the capture device, to adjust information content in the digital output(b) receives and pre-processes the digital output in real time to select the ROI in each of the a least two images individually;(c) extracts a pulse wave sample from the ROI for each of the at least two images, the extracted pulse wave sample corresponding to a single time point, the preprocessing including separating the digital output into red light data, green light data, and blue light data and calculating a ratio of red light data to green light data;(d) combines multiple color planes information, such as hue, saturation, luminance, intensity, and value, with the red light, green light, and blue light data to modify the extracted pulse wave sample(e) (e) generates a pulse wave sample by ...

PROCESSES AND SYSTEMS FOR IMPROVEMENT OF HEAVY CRUDE OIL USING INDUCTION HEATING

Embodiments of the present invention include a novel continuous or semi-continuous process which results in the partial or total improvement of heavy oil. The improvement of the heavy oil is a result of thermally heating the oil at an interval where visbreaking occurs, thereby reducing a viscosity of the heavy oil. The core of the heating step occurs through a heating apparatus of the packed bed type including superparamagnetic, paramagnetic, and/or magnetic materials. 1. A continuous or semi-continuous process for improving heavy oil by visbreaking , the process comprising:introducing the heavy oil into a heating apparatus comprising a packed-bed type, wherein the heating apparatus contains materials selected from the group consisting of superparamagnetic materials, paramagnetic materials, ferromagnetic materials, and combinations thereof.2. A visbreaking system comprising a heating apparatus or reactor wherein a fluid temperature therein is increased using the heating apparatus through induction heating.3. A heavy oil induction heating apparatus in which a fluid flowing therethrough is heated to a specific temperature such that a visbreaking phenomena occurs , the apparatus comprising:A) an electrical power source that generates an alternating current of high frequency;B) a magnetic induction heating coil wherein the current emanated by A) flows;C) an electrically non-conductive annular casing comprising a tube, pipe, or similar, wherein the casing has a fluid entrance port and a fluid outlet port; andD) between said ports, an induction heating structure responsive to the magnetic field produced in B), wherein said induction heating structure is formed of independently moving parts, solid parts, or a combination of both.4. The apparatus of claim 3 , wherein the parts of the heating structure contain particles which respond according to the Neel relaxation phenomenon to induce heating of the fluid.5. The apparatus of claim 4 , wherein the heating structure further ...

METHOD FOR LABELING NANOCLAY FOR TRACKING THEM WITHIN DIFFERENT SOLID AND LIQUID MATERIAL

A method of monitoring a location of a nanoparticle within a material is described herein. The method includes the steps of providing at least one nanoclay particle, attaching a fluorescent tag to the at least one nanoclay particle, and determining a fluorescence of the fluorescent-labeled nanoclay particle. The method also includes forming the material including the at least one fluorescent-labeled nanoclay particle, depositing the material in an aqueous solution, and detecting a movement of the fluorescent-labeled nanoclay particle from the material to the aqueous solution. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. A nanoparticle prepared by a process comprising the steps of:providing a nanoclay particle including organically modified montmorillonite (o-MMT);reacting the nanoclay particle with a solution including mercaptosilane to convert a hydroxyl of the o-MMT to a thiol moiety and produce a mercaptosilane modified nanoclay particle; and,reacting the mercaptosilane modified nanoclay particle with a thiol-reactive dye, the thiol-reactive dye including a fluorescent tag, to attach the fluorescent tag to the thiol moiety of the mercaptosilane modified nanoclay particle with a covalent bond to form a fluorescent-labeled nanoclay particle.9. (canceled)10. (canceled)11. A nanoparticle in accordance with claim 8 , wherein the fluorescent tag is selected from a group consisting of fluorescein and rhodamine.12. A nanoparticle in accordance with claim 8 , wherein the step of reacting the nanoclay particle with a solution including mercaptosilane further includes the steps of:dispersing the nanoclay particle in an aqueous solution to form a clay dispersion; andmixing the solution including mercaptosilane with the clay dispersion to facilitate reacting the nanoclay particle with the mercaptosilane to form the mercaptosilane modified nanoclay particle.13. A nanocomposite film prepared by a process comprising the steps of: ...

CONVEYOR AND CONVEYOR SYSTEM

A conveyor comprising a first profile unit () and a second profile unit (), wherein the profile units comprise a support profile () and a side profile () that can be releasably connected to each other to form a composed structure whose cross-sections comprise lateral openings (), at least one conveyor unit () that can be arranged between the two profile units, wherein each conveyor unit () comprises a first side wall () and a second side wall (), and wherein conveying elements () are arranged between the side walls (), wherein the side walls () can be releasably arranged in the lateral openings () of the profile units () to form composed structures with a closed cross-section. 1. A conveyor comprising{'b': 1', '2', '1', '2', '3', '1', '10', '11', '10', '11', '12', '2', '20', '21', '20', '21', '22', '12', '22, 'a first profile unit () extending in a conveying direction (L) and a second profile unit () extending in the conveying direction (L), the first profile unit () and the second profile unit () being arranged parallel to each other and being fixed to each other by means of at least one profile crossbeam (), wherein the first profile unit () comprises a support profile () and a side profile () that can be releasably connected to each other to form a composed structure (, ) whose cross-section comprises a first lateral opening () and wherein the second profile unit () comprises a support profile () and a side profile () that can be releasably connected to each other to form a composed structure (, ) whose cross-section comprises a second lateral opening (), wherein the first lateral opening () faces the second lateral opening (),'}{'b': 4', '1', '2', '4', '40', '41', '40', '41', '44', '45', '40', '41, 'at least one conveyor unit () that can be arranged between the first profile unit () and the second profile unit (), wherein each conveyor unit () comprises a first side wall () and a second side wall (), the first side wall () and the second side wall () being ...

COMPUTATIONAL METROLOGY

A method, involving determining a first distribution of a first parameter associated with an error or residual in performing a device manufacturing process; determining a second distribution of a second parameter associated with an error or residual in performing the device manufacturing process; and determining a distribution of a parameter of interest associated with the device manufacturing process using a function operating on the first and second distributions. The function may include a correlation. 1. A method , comprising:determining a first distribution of a first parameter associated with an error or residual in performing a device manufacturing process;determining a second distribution of a second parameter associated with an error or residual in performing the device manufacturing process; anddetermining, by a hardware computer, a distribution of a parameter of interest associated with the device manufacturing process using a function operating on the first and second distributions.2. The method of claim 1 , wherein the first parameter claim 1 , the second parameter and the parameter of interest are the same.3. The method of claim 1 , wherein the first distribution is specific to the device manufacturing process but not specific to any particular substrate processed using the device manufacturing process.4. The method of claim 1 , wherein the second distribution is specific to a particular substrate processed using the device manufacturing process but not generic to other substrates processed using the device manufacturing process.5. The method of claim 1 , wherein the first distribution and/or second distribution comprises one or more selected from: a contribution of a servo error to the respective first and/or second parameter claim 1 , a contribution of an alignment model residual to the respective first and/or second parameter claim 1 , a contribution of a projection system aberration or image plane deviation to the respective first and/or second ...

ORIENTATION SYSTEM FOR PRODUCT CONVEYORS

An orientation system for conveyors of products designed to divert the latter from a primary feed direction to a secondary feed direction and comprising a plurality of orienting units. Each orienting unit comprises a transporting element rotatable around a rotation axis and an actuating member to actuate the rotation of at least one transporting element so as to control the rotation of a transporting element. The actuating member comprises a primary transmission element and a planet transmission element designed to be coupled to the primary transmission element; at least two housing seats for respective planet transmission elements being designed to transmit the rotation motion of the transporting element to an adjacent orienting unit. 1. An orientation system for conveyors of products designed to divert said products from a primary feed direction to a secondary feed direction , the orientation system comprising:a plurality of orienting units arranged adjacent so as to form a plane for transporting said products, each orienting unit comprising at least one transporting element rotatable around a rotation axis that can be oriented with respect to a vertical axis orthogonal to said primary feed direction and to said rotation axis itself, each orienting units comprising at least one actuating member to actuate a rotation of said at least one transporting element to control the rotation of said at least one transporting element around said rotation axis and at least one drive shaft arranged according to said vertical axis (Z); at least one primary transmission element keyed on said drive shaft;', 'at least one planet transmission element designed to be operatively coupled to said primary transmission element;', 'at least two housing seats for at least one planet transmission element; and, 'wherein said actuating member compriseswherein said planet transmission element is configured to be selectively and reversibly coupled in at least one of said housing seats so as to ...

Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.

Fus1/tusc2 therapies

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by adminsirtation of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

Surface cross-linked lipidic particles, methods of production and uses therefor

A method for producing a composition of lipidic particles coated with a cross-linked surface mesh, the method comprising the steps of: (i) preparing lipidic particles comprising pharmaceutically acceptable lipids, (ii) binding hydrophilic polymer chains to the surface of the lipidic particles, and (iii) cross- linking the hydrophilic polymer chains to form the cross-linked surface mesh. Pharmaceutical compositions comprising surface modified lipidic particles prepared according to this method are also described. The lipidic particles resist fusion with red blood cells and platelets in vitro, and are amenable to further derivatization by targeting molecules for controlled release of component and contents, thus providing a new generation of drug carrier systems.

Assembly set for erecting roller conveyors

An assembly set for erecting roller conveyors includes a plurality of structural elements each of which has a housing provided in its upper side with a recess in which a spherical or cylindrical rolling element is turnably accommodated with a portion thereof projecting upwardly beyond the upper side so as to contact and support a load which is to be transported. Releasable connecting means, separate from or provided on the respective structural elements, serves for releasably connecting the same to one another so as to enable the construction of differently configurated roller conveyors at the will of a user.

Synthetic platelets

A synthetic platelet substitute that interacts with platelets and the (sub)endothelium, comprising: (a) a carrier molecule comprising lipidic particles with a cross-linked surface mesh, the lipidic particles comprising: an inner lipidic particle of pharmaceutically acceptable particle-forming lipids; hydrophilic polymer chains linked to the surface of the lipidic particle, the hydrophilic polymer chains comprising a crosslinkable end group at free ends thereof; and cross-linker groups linking the end groups of the hydrophilic polymer chains to form the cross-linked surface mesh; and (b) at least one receptor molecule attached to the surface of the carrier molecule. The receptor molecule can be a peptide moiety specific for ligands involved in platelet function.

Blade and motor carrier with height/angle adjustment mechanism

A machine tool has a work table which defines a working surface and has a cutting tool which is attached to and movable with respect to the work table. The position of the cutting tool with respect to the working surface is controlled by a mechanism which elevates the cutting tool with respect to the working surface and angulates the cutting tool with respect to the working surface. The cutting tool is mounted to a support plate which is pivotably attached to the work table. The elevating mechanism includes a threaded rod and a nut which engages a pivoting link. The pivoting link also engages the cutting tool. Rotation of the threaded rod pivots the link which in turn raises and lowers the cutting tool. A spring biases the cutting tool towards its lower position to remove play between the components. The angulating mechanism includes a lever, two cams and a locking rod. Rotation of the lever moves the locking rod longitudinally due to the action between the two cams. The longitudinal movement of the rod compresses the support plate between the work table and a bracket to maintain the position of the support plate with respect to the work table. Also included is an integral arbor wrench which is accessible when the throat plate is removed to lock the arbor to facilitate tool changing. The wrench is designed to not allow reassembling of the throat plate when the wrench is in engagement with the arbor shaft.

Process for the preparation of portland cement clinker

ABSTRACT OF THE DISCLOSURE A process for the preparation of portland cement clinker resides in that limey, clayey and iron-containing components are ground together. The mix is then homogenized pelletized, decar-bonized at a temperature of from 800° to 1000° and roasted at a temperature of from 1200° to 1350°C. Dust sublimates which are wastes of the titanium production, are added at the stage of grinding or homogenization in an amount of 0.5 to 6.0% by total weight of raw mix, and or addition of the dust sublimate at the homogenization stage, an aqueous suspension of cakes which are wastes of the titanium and magnesium production and comprise a paste-like mass with a moisture content of 60 to 80% is added at the pelletizing stage, at a volumetric ratio of water to cakes of 3-6:1, and in an amount of 10 to 14% by total weight of raw mix. The process according to the invention enables the preparation of clinker exhibiting an improved strength. With the process according to the invention, the degree of decarbonization of raw mix is as high as 35-50%, and roasting temperature is 120°-150°C lower.

Electrolytic system and method for filtering an aqueous particulate suspension

An electrolytic filtration method and apparatus for the concentration and collection of suspended particulates from aqueous solutions is disclosed. The electrolytic cell contains at least an anode and a cathode, and in one embodiment contains a plurality of anodes and cathodes. The electrolytic cell also contains a filter, and in one embodiment the filter is a moving belt filter. While not bound by theory, the electrolytic filtration method and apparatus is based on the electrophoretic movement of algae particles suspended in an aqueous solution away from the filter under the influence of an electric field. In one embodiment the electric field is a pulsed waveform with unidirectional voltage or current pulses. In another embodiment, the electric field is a pulsed waveform with bidirectional voltage or current pulses.

Power semiconductor module method

A method for assembling a power module includes providing a casing with a plurality of receiving elements. At least one substrate carrying at least one semiconductor chip is provided within the casing. At least one support element is provided. An elastically stressed cover is arranged over the at least one support element, and the cover is released so that the elastically stressed cover is restrained by the at least one support element and the plurality of receiving elements.

STRUCTURE WITH BIACHSIAL TEXTURE AND METHOD FOR THE PRODUCTION THEREOF

Preparation of hyaluronic acid used in cosmetics and clinical work comprises proteic electrodeposition based on fish vitreous humor

Preparation of hyaluronic acid (AH) comprises proteic electrodeposition and simultaneous diafiltration with total recirculation, based on fish vitreous humor. Selective recuperation of impure sediments, precipitation of AH and solubilization of proteins with dissolving of the AH yielding over 99.5 per cent pure AH.

Method for producing the anticholinergic agent tiotropium bromide

Process for the production of vanadium-containing steel alloys

A process for production of vanadium-containing agglomerate, includes the steps of providing a spent, vanadium-containing, iron based hydroconversion catalyst; incinerating the spent catalyst in the presence of an oxidizer until a sulfur content of the spent catalyst is reduced to 2% or less by weight; grinding the spent catalyst to a particle size suitable for a desired use; and mixing the spent catalyst with an iron mineral and a binder to form a vanadium-containing agglomerate; and pyroconsolidating the vanadium-containing agglomerate. Agglomerates so obtained exhibit a solid solution structure of ferric oxide and vanadium pentoxide. A process for production of vanadium-containing steel alloys from such agglomerates includes the steps of: reducing the vanadium-containing agglomerate; mixing the reduced vanadium-containing agglomerate with a standard reduced iron agglomerate to obtain a mixed reduced agglomerate; and melting the mixed reduced agglomerate under reducing conditions to obtain a vanadium-containing steel alloy.

Method for production of wall covering panels, and panel obtained with said method

Especially designed for replacing standard panels based on ceramic plates, the invention consists in putting a design (2) on the back side of a core or panel (1) of metacrylate, polycarbonate or other similar transparent plastic material, a design which is partly removed by milled slots or grooves (3), positioned for example to match the original joint lines for ceramic pieces; a layer o paint (4) is applied to said back face (4) and is visible through the background of said grooves (3) and visually enhances the appearance of said joints, while in the front face (5) of the assembly slots (6) are set to positionally match the lower slots (5) which give a bas-relief effect to the panel, wherein the front face is coated with a protective epoxy resin or other similar transparent material. The above method provides a panel which imitates standard tiling, but is much lighter, more easily fitted and with better features.

Secure identity provider authentication for native application to access web service

A native application on a client computing device enables secure user authentication via an identity provider (IdP) for accessing services of a web service provider. The native application forwards a redirect request generated by a main gateway of the service provider and including an IdP uniform resource locator (URL) to a system browser of the client computing device. The redirect request directs the system browser to a broker gateway of the service provider that registers an authentication response handler and redirects the system browser to the IdP URL to enable a user of the native client computing device to authenticate. After the broker gateway receives an IdP authentication response from the IdP following authentication by the user, the broker gateway provides the IdP authentication response to the native application for providing back to the main gateway. The main gateway finally processes the authentication response to complete the authentication request.

Web based data collaboration tool

A web based data collaboration tool includes a dynamic international collaborative environment in which system partners, including customers, technology partners and suppliers, can exchange information between one another in a truly collaborative environment. The web based data collaboration tool includes unique "fine grain" security at both the document and sub-document level. This allows one source document to be shared between the system partners, including partners from different companies and those located in different countries, based upon an individual document/sub-document security profile. Further, the web based data collaboration tool includes a secure "Sandbox" for peer-to-peer sharing of sensitive documents and electronically incorporates a business area export representative (BAER) approval process that includes the required retention of International Traffic in Arms Regulations (ITAR) documents making the web based data collaboration tool fully ITAR compliant.

Masp-2 inhibitors and methods of use

The present disclosure provides, inter alia , compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Advanced call forwarding

The present invention advantageously provides a method and system that combines arming and disarming of a security system with activation and deactivation of call forwarding, enabling a single input by an authorized user to alter the state of the security system and to activate or deactivate call forwarding. Further, when changing the state of the security system, a user authorization component determines whether call forwarding should be activated. Hence, forwarding of calls is based on both user criteria and the state of the system. Additionally, the state of call forwarding can be changed by an authorized user via the security system.

Masp-2 inhibitors and methods of use

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

Crystalline monohydrate of tiotropium bromide, method for producing the same, pharmaceutical composition comprising same and the use thereof

The invention relates to a crystalline tiotropium bromide monohydrate of ((1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.0<2,4>]nonane bromide), to a method for producing the same, a pharmaceutical composition consists of thereof and to the use thereof for producing a medicament that has an anticholinergic effect.

Systems and methods for utilizing an application from a native portable device within a non-native communications network

The disclosed systems and methods include a native portable communications device having an application module that modifies communications between the portable device and a non-native communications device connected to a non-native communications network. The application module transforms communications between a native standard to a non-native standard to allow interoperability between the native portable communications device and the non-native communications device within the non-native communications network. Further, the application module may modify communications in other manners, such as to apply a security function to the communication. Additionally, the systems and methods may include a communications accessory for switching communications between the application module of the native device, the non-native device, and the non-native network. Thus, the native portable communications device and the associated methods of operation with the application module provide a mobile system that enables modified communications over various communications networks.

Crystalline monohydrate, mehod for producing the same and the use thereof in the production of a medicament

Pronalazak se odnosi na kristalni monohidrat (1α,2ГЎ,4ГЎ,5α,7ГЎ)-7-[(hidroksi-2-tienilacetil)oksi]-9,9-dimetil-3-oksa-9-azoniatriciklo-[3.3.1.02.4]nonan-bromida, na postupak za njegovo pripremanje, kao i na njegovu primenu za pripremanje leka, naročito za pripremanje leka sa antiholinergijskim dejstvom.[The invention relates to a crystalline monohydrate of (1α,2ГЎ,4ГЎ,5α,7ГЎ)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatrycyclo[3.3.1.02,4]nonane bromide, to a method for producing the same, and to the use thereof in the production of a medicament, especially for producing a medicament that has an anticholinergic effect.

THYROID BROMETER CRYSTAL MONO-HYDRATE, PROCESS FOR PREPARING AND USING THE PREPARATION OF A MEDICATION

PROCESS AND ARRANGEMENT FOR THE PREPARATION OF SUNFLOWER SEEDS BY DECORTICATION FOR THE EXTRACTION OF SUBSEQUENT OIL.

Sunflower seed peel separator - classifies granule size and separates peel using tilted sieving boxes and special electrical separator

On a screwed profile steel frame two inclined, independent, freely vibrating sieve boxes (1) are located. The upper and lower (1.1,1.2) boxes have a single pulley belt drive on eccentric shafts, and the seive entries (2) have sieves with holes of 3.0 x 22.0 mm. On the upper sieve box directly behind the inlet (3) and at the rear lower end, on the lower sieve box (1.2) at the rear end, are material withdrawal points which issue into input funnels (4). The input funnels are part of a double electrical separator, the rollers (5) of which are located beneath the electrode holders (6) material pick-up funnel (7) with separators (8). USE - For the processing of sunflower seeds prior to oil extraction, effecting granule size classification and peel sepn.

Integrated digital-analog archiving systems and methods for document preservation

An integrated digital-analog archiving system can automatically initiate a migration process to move electronic documents to a media library. For each electronic document, the system may retrieve the electronic document from a digital data storage medium, extract metadata from the electronic document, determine size, orientation, and format of the electronic document, generate indicators for indicating the start and end of the electronic document to be stored on an analog data storage medium, generate an analog document identifier for identifying the electronic document on the analog data storage medium, generate a scaled image of the electronic document based on the size, orientation, and format of the electronic document, generate a text string based at least in part on the extracted metadata, and render the indicators, the analog document identifier, the scaled image of the electronic document, and the text string on the analog data storage medium.

Control of modular multilevel series/parallel converters (mmspc) by means of switching tables and continuous background optimisation thereof

The invention relates to a method for controlling (300) switching states of a multilevel converter, in which the control is divided into a real-time part (320) and an offline-part (310). In the real-time part, a respective voltage (325) is assigned for each time interval of a respective voltage requirement (324) by a modulator (322), and at the respective voltage level a scheduler (323) determines a respective switching state of all switches in a first switching table, and the respective switching state is relayed as control signal (302) to all switches of the multilevel converter. In the offline part, an optimal second switching table (312, 313) is calculated by an optimiser (311) in a continuous succession according to a cost function. After the calculation is completed, the calculated second switching table replaces the first switching table and thereby becomes a first switching table.

window profile

Fensterprofil, insbesondere ein Rahmen-, Flügel-, Pfosten- oder Sprossenprofil und in Form eines Kunststoffprofils (1) ausgebildet, für Fenster-, Türen-, Festverglasungen und dergleichen, wobei das Kunststoffprofil (1) aus Hauptkammer- und Vorkammeranordnungen herausgebildet ist, in denen ein Verstärkungselement (7), weitere Kammern (11 bis 11 n ) im jeweiligen Kunststoffprofil (1) bildend, angeordnet ist, wobei das Verstärkungselement (7) als ein länglicher Hohlkörper (9) mit an seinem äußeren Umfang vorgesehenen und axial verlaufenden Streben (10) ausgebildet ist, wobei die Streben (10) des Hohlkörpers (9) diagonal verlaufend in der Hauptkammer (4; 5) angeordnet und zu den Eckverbindungen der Hauptkammer (4; 5) verbunden sind, dadurch gekennzeichnet, dass der Hohlkörper (9) mit einem kreisförmigen Querschnitt ausgebildet ist. Window profile, in particular a frame, wing, post or rung profile and in the form of a plastic profile (1) formed for window, door, fixed glazing and the like, wherein the plastic profile (1) of Hauptkammer- and Vorkammeranordnungen is formed, in in which a reinforcing element (7), further chambers (11 to 11 n ) in the respective plastic profile (1) forming, is arranged, wherein the reinforcing element (7) as an elongated hollow body (9) provided on its outer circumference and axially extending struts ( 10), wherein the struts (10) of the hollow body (9) are arranged diagonally in the main chamber (4, 5) and connected to the corner joints of the main chamber (4, 5), characterized in that the hollow body (9) is formed with a circular cross-section.

Use of biguanide derivatives for making a medicine having a wound healing effect

Производните на бигуанидина имат формула@@в коятогрупите R1 и R2 независимо една от друга означават водороден атом, алкилна група с С1-С7, циклоалкилна група, хетероцикъл, алкенилна група с С2-С7, арилна група, аралкилна група, арилоксиалкилна група или хетероарилна група, или R1 и R2 взети заедноозначават алкилен с С2-С7, който може да съдържа един или повече хетероатоми, а групата R3 означавапървичен, вторичен или третичен амин. Изобретението се отнася и до фармацевтично приемливи соли на посочените съединения за получаване на лекарствено средство, проявяващо цикатризиращ ефект.

Method of positioning and rotating workpiece and arrangement implementing same

A method for positioning and rotating a workpiece shaped like a body of rotation and having a plane face, comprising the following steps: positioning the workpiece on an axial and a radial supports; transmitting the torque from a rotary driving member to the workpiece due to the forces of friction developed therebetween; and feeding ultrasonic mechanical vibrations to at least one of the supports, said vibrations being fed to any one of the supports in the direction substantially parallel to or at an angle not exceeding 10 degrees with the line of contact between the workpiece and said support. An arrangement implementing this method comprises separate axial and radial supports, the radial support being constituted by two parts spaced apart through a certain angle and having the profile, in the working portion, congruent to the cylindrical profile of the workpiece surface. The arrangement is further provided with a frictional rotary driving member contacting with the workpiece to be machined, and with an electromechanical magnetostriction converter operating within the ultrasonic range and having a waveguide rigidly connected to both converter and support, mechanical vibrations being fed thereto.

R-(z)-4-amino-3-chloro-2-pentenedioic acid, novel antibacterial agent

TITLE OF THE INVENTION R-(Z)-4-AMINO-3-CHLORO-2-PENTENEDIOIC ACID, NOVEL ANTIBACTERIAL AGENT ABSTRACT OF THE DISCLOSURE R-(Z)-4-amino-3-chloro-2-pentenedioic acid is a novel antibacterial and isolated from Streptomyces viridogenes MA5450, ATCC 39387.

Masp-2 inhibitors and methods of use

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

Choke coil comprising a bead of a soft-magnetic material

The choke coil comprises a bead of a soft-magnetic material in which a number of ducts extend in parallel. An electrically conductive wire comprising fee ends is accommodated in the ducts. The choke coil comprises means for shielding a portion of the turn which extends outside the ducts. To this end, for example an electrically insulating housing is arranged around the bead. The housing consists of two approximately cylindrical portions, each of which comprises a substantially closed end face which is situated on a first end portion. The cylindrical portions are axially slid over the bead with their second open end portion fitting one into the other. In each end face there is provided at least one opening for feeding out the wire. When the choke coil is also provided with electrically insulating caps having a wire passage in the prolongation of the axis of the bead, the wire fed out will be oriented along said axis.

ROLL FOR TRANSPORT SYSTEMS

Raw mix for producing portland cement clinker

RAW MIX FOR PRODUCING PORTLAND CEMENT CLINKER Abstract of the Disclosure According to the invention, the raw mix for producing portland cement clinker comprises a lime component, a clay component, an iron-containing component and a modifying agent. The latter is a cake byproduct readily available at titanium and magnesium works. The percentage by weight composition of the mix is as follows: lime component, 88.3 to 77.8 clay component, 9.2 to 11.2 iron containing component, 2.0 to 5.0 modifying agent, 0.5 to 6.0 The raw mix according to the invention possesses better properties than conventional mixes. For example, its plasticity is 140 to 160 units, and the degree of mineralization is as high as 19 percent.

A method of predicting a response to a tusc2 therapy

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by adminsirtation of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

PROCESS FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINES

Die Erfindung betrifft ein Verfahren zur Herstellung von 1,4-Dihydropyridinen der allgemeinen Formel I, worin die Substituenten die in der Beschreibung genannte Bedeutung besitzen. Die neuen Verbindungen zeigen wirksame Eigenschaften als Kalziumantagonist und koennen bei der Behandlung von Hypertension, Angina pectoris und anderen vaskulaeren Erkrankungen eingesetzt werden. Formel I The invention relates to a process for the preparation of 1,4-dihydropyridines of the general formula I in which the substituents have the meaning given in the description. The new compounds exhibit potent calcium antagonist properties and can be used in the treatment of hypertension, angina pectoris and other vascular diseases. Formula I

Platelet additive solution

A platelet additive solution (PAS) comprising a viscosity increasing agent. The use of a PAS comprising such a viscosity increasing agent, especially at concentrations effective to achieve a viscosity similar to that of blood plasma, promotes platelet recovery during extraction from pooled buffy coats and provides for easier platelet production by maintaining the red cell/platelet-rich-supernatant interface.

Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament

chop saw

CRYSTALLINE MONOHIDRATE, PROCEDURE FOR PREPARATION AND USE FOR PREPARATION OF A MEDICINAL PRODUCT

El invento se refiere a un monohidrato cristalino de bromuro de (1 alfa, 2 beta, 4 beta, 5 alfa, 7 beta) - 7 - ( hidroxi - di - 2 - tienil - acetil) oxil) - 9, 9 - dimetil - 3 - oxa -9- azonia - triciclo (3.3.1.0. 2,4) nonano, a un procedimiento para su preparación, así como a su utilización para la preparación de un medicamento, particularmente para la preparación de un medicamento con efecto anticolinérgico. The invention relates to a crystalline bromide monohydrate of (1 alpha, 2 beta, 4 beta, 5 alpha, 7 beta) -7 - (hydroxy-di-2-thienyl-acetyl) oxyl) -9,9-dimethyl- 3-oxa -9- azonia-tricycle (3.3.1.0. 2,4) nonane, to a process for its preparation, as well as to its use for the preparation of a medicament, particularly for the preparation of a medicament with anticholinergic effect.

PROCESS FOR OBTAINING SLOW SOLUBILIZATION DIAMMONIUM PHOSPHATE-TYPE FERTILIZERS

Bevel stop mechanism for a miter saw

Method for producing the anticholinergic tiotropium bromide

The invention relates to a novel method for producing (1.alpha., 2 .beta., 4 .beta., 5.alpha., 7 .beta.)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4-]nonane bromide. In the method, tiotropium bromide of formula (I) SEE FORMULA I is obtained through a reaction of tropenol of formula (V) SEE FORMULA V with di-(2-thienyl)-glycolic acid derivatives of formula (VI) SEE FORMULA VI to form a tropenol ester of formula (VII) SEE FORMULA VII which is converted to a scopine ester of formula (IV) SEE FORMULA IV by epoxidation, with the subsequent quaternisation of the scopine ester with methyl bromide to produce the tiotropium bromide of formula (I).

Blade and motor carrier with height/angle adjustment mechanism

A machine tool has a work table which defines a working surface and has a cutting tool which is attached to and movable with respect to the work table. The position of the cutting tool with respect to the working surface is controlled by a mechanism which elevates the cutting tool with respect to the working surface and angulates the cutting tool with respect to the working surface. The cutting tool is mounted to a support plate which is pivotably attached to the work table. The elevating mechanism includes a threaded rod and a nut which engages a pivoting link. The pivoting link also engages the cutting tool. Rotation of the threaded rod pivots the link which in turn raises and lowers the cutting tool. A spring biases the cutting tool towards its lower position to remove play between the components. The angulating mechanism includes a lever, two cams and a locking rod. Rotation of the lever moves the locking rod longitudinally due to the action between the two cams. The longitudinal movement of the rod compresses the support plate between the work table and a bracket to maintain the position of the support plate with respect to the work table. Also included is an integral arbor wrench which is accessible when the throat plate is removed to lock the arbor to facilitate tool changing. The wrench is designed to not allow reassembling of the throat plate when the wrench is in engagement with the arbor shaft.

Method for desalting crude oil

ABSTRACT OF THE DISCLOSURE METHOD FOR DESALTING CRUDE OIL The salt content of a heavy crude oil is reduced by a method which comprises the steps of (a) mixing 70 to 98% by volume of a heavy crude oil having a viscosity in the range 200 to 250,000 mPa.s at the mixing temperature with 30 to 2% by volume of an aqueous solution of an emulsifying surfactant or an alkali, percentages being expressed as percentages by volume of the total mixture; mixing being effected under low shear conditions in the range 10 to 1,000 reciprocal seconds, in such manner that an HIPR emulsion is formed comprising distorted oil droplets having mean droplet diameters in the range 2 to 50 micron separated by aqueous films, (b) breaking the resulting emulsion, and (c) separating the resulting mixture into a layer of relatively salt-free oil and a layer of relatively salt-enhanced water. Heavy crude oils are desalted by the above method without requiring a hydrocarbon diluent. The high surface area of the aqueous lamellae in the HIPR emulsion increases the probability of contacts occurring between them and the droplets of salt water originally present in the crude oil, and thus leads to greater desalting efficiency.

Miter saw

R-(Z)-4-amino-3-chloro-2-pentenedioic acid, novel antibacterial agent

R-(Z)-4-amino-3-chloro-2-pentenedioic acid is a novel antibacterial and isolated from Streptomyces viridogenes MA5450, ATCC 39387.

R-(z)-4-amino-3-chloro-2-pentenedioic acid, novel antibacterial agent

R- (Z) -4-AMINO-3-CHLORO-2-PENTEN-DICARBONIC ACID, ANTIBACTERIAL AGENT.

Flat flame burner

In a flat flame burner fuel gas is admitted to a mixing chamber (2) from a pipe (1) via a ring (3) which is formed with oblique slots or bores to rotate the gas. The ring (3) surrounds a core (4) which may be an oil supply pipe, an igniter or a monitoring device. Air from a pipe (13) is admitted to the mixing chamber (2) through an array (6) of blades each oblique to the axis (x) of the burner and terminating at a frusto- conical deflecting face (7). By means of a device (9) the position of the fuel supply (1,3,4) relative to the air admission means (6) is adjustable axially of the burner to accommodate different operating conditions and the use of different fuels or mixtures of fuels. <IMAGE>

CRYSTALLINE BOTTURE MONOTHYRATE OF TIOTROPIO, PROCEDURE FOR PREPARATION AND USE FOR THE PRODUCTION OF A MEDICINAL PRODUCT.

Bromuro de tiotropio monohidrato, cristalino. Se encontró, que el bromuro de tiotropio resulta en diferentes modificaciones cristalinas, según se elijan las condiciones que se pueden aplicar en la purificación del producto bruto obtenido después de la preparación técnica. Se encontró, que estas diferentes modificaciones se pueden obtener regularmente, de manera preestablecida, por elección de los disolventes empleados para la cristalización, así como por elección de las condiciones del procedimiento elegidas en el proceso de cristalización. Se comprobó, sorprendentemente, que el bromuro de tiotropio monohidrato, el cual se puede obtener en forma cristalina por elección de condiciones de reacción específicas, satisface las elevadas exigencias citadas al comienzo y, con ello, soluciona el problema en el que se fundamenta el presente invento. De forma correspondiente, el presente invento se refiere a bromuro de tiotropio monohidrato. Otro aspecto del presente invento se refiere a un procedimiento de preparación de hidratos cristalinos de bromuro de tiotropio. Este procedimiento de preparación se caracteriza, porque el bromuro de tiotropio se recoge en agua, la mezcla obtenida se calienta y, a continuación, bajo lento enfriamiento, cristalizan los hidratos de bromuro de tiotropio. El presente invento se refiere, además, a los hidratos cristalinos de bromuro de tiotropio, los cuales se pueden obtener por el modo de proceder anterior. Un aspecto del presente invento se refiere a un procedimiento de producción de bromuro de tiotropio monohidrato, cristalino, el cual se describe detalladamente a continuación. Para la preparación del monohidrato cristalino conforme al presente invento es necesario recoger en agua el bromuro de tiotropio que se ha obtenido, por ejemplo, según la prescripción de producción, calentarlo, llevar a cabo una purificación con carbón activo y, después de separar el carbón activo, bajo lento enfriamiento, cristalizar lentamente el bromuro de tiotropio ...

Integrated digital-analog archiving systems and methods for document preservation

An integrated digital-analog archiving system can automatically initiate a migration process to move electronic documents to a media library. For each electronic document, the system may retrieve the electronic document from a digital data storage medium, extract metadata from the electronic document, determine size, orientation, and format of the electronic document, generate indicators for indicating the start and end of the electronic document to be stored on an analog data storage medium, generate an analog document identifier for identifying the electronic document on the analog data storage medium, generate a scaled image of the electronic document based on the size, orientation, and format of the electronic document, generate a text string based at least in part on the extracted metadata, and render the indicators, the analog document identifier, the scaled image of the electronic document, and the text string on the analog data storage medium.

Vector containing Mycobacterium tuberculosis 38 kDa antigen for the treatment of neoplasms

Plastic profile for window frame or doorframe has main void with co-extruded strengthening member supported by struts

A window or door frame is fabricated from an extruded plastic profile with internal partitions forming a main void and a number of smaller secondary voids. The main void is further sub-divided by co-extruded strengthening elements (7) supported by struts (10) forming additional sub-chambers.

Throat plate for a tool

An improved throat plate is disclosed herein. The throat plate includes a main body, an opening in the main body for allowing a cutting tool to extend therethrough, and a retainer assembly attached to the main body for retaining the throat plate in contact with the table. Preferably the retainer assembly is pivotally attached to the main body and/or is movable between a first position contacting the table and a second position bypassing the table. The retaining assembly may pivot about an axis substantially perpendicular to a plane of the table. The retainer assembly may also include an extension that contacts underside of the table. The extension in turn may include a camming surface contacting the underside of the table.

Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis

The invention relates to the production of ovoproducts containing bioactive peptides from the egg white subjected to enzymatic treatment. Said peptides have an inhibiting activity of the angiotensin converting enzyme (ACE inhibiting activity) in vitro and/or anti-hypertensive activity in rats and/or antioxidant activity. Said ovoproducts, complete hydrolizates, the fractions thereof with low molecular weight or their constituent peptides could be used as therapeutic substances with ACE inhibiting activity and/or anti-hypertensive activity and/or anti-oxidant activity, either as functional food products, food additives or ingredients or pharmaceutical products for the treatment and/or prevention of hypertension in all its forms in humans or animals and for the treatment and/or prevention of any disorder associated with hypertension in humans or animals.

METHOD FOR CONCENTRATING NANOSUS PENSIONS

Crystalline monohydrate, process for its preparation and use thereof for the manufacture of a drug

Anti-GDF15 antibodies

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Glue gun holder

Compositions and methods for preventing or reducing inflammation by inhibiting caspase-9

The present disclosure relates to a method of preventing or decreasing inflammation in a patient comprising administering to the patient in need thereof an effective amount of a caspase-9 signaling pathway inhibitor. The caspase-9 signaling pathway inhibitor may include a peptide caspase-9 inhibitor and/or may be conjugated to a cell-penetrating peptide. The present disclosure further includes pharmaceutical compositions including a caspase-9 signaling pathway inhibitor. The disclosure further relates to the use of such compositions in a method of treating inflammation of the retina associated with retinal vein occlusion, diabetic macular edema, retinal detachment, ocular trauma, retinitis pigmentosa, age-related macular degeneration, uveitis, a retinal degenerative disease, glaucoma, Multiple sclerosis, Behcets, Lupus, Systemic sarcoidosis, Central serous chorioretinopathy, Leber's Hereditary Optic Neuropathy, Leigh Syndrome, Stargardt, retinitis pigmentosa, Best disease, or birdshot retinopathy.

Platelet Additive Solution

Novel visible spectrum dye lasers

A lasing medium is disclosed containing certain pyrylium and benzopyrylium organic dyes which are capable of laser emission in the 500-600 nanometer region.

Mimotope receptors and inhibitors for platelet- platelet and platelet-endothelium interactions

Mimotope receptors and inhibitors employ peptide mimics that mimic the shape and function of natural receptors and ligands, thus providing synthetic binding sites for ligands and receptors. Receptor mimics can be attached to carriers, such as liposomes, to act as synthetic platelets, for example, by providing binding sites for binding to other (natural or synthetic) platelets or to the endothelium. Synthetic platelets would have virtually limitless shelf life and would not require disease screening prior to transfusion, thereby providing a solution to the perpetual platelet shortages, as well as the safety and storage issues associated with natural blood platelets. Mimotope inhibitors (either free- molecule receptors or ligands) can act as antithrombotics by inhibiting platelet-platelet or platelet-endothelium interactions. Ligand mimics are preferably D-peptides that resist proteolytic degradation. Furthermore, these ligand mimics can also be attached to carriers for resisting excretion, thus forming the new class of antithrombotic drugs.

Verfahren und System zu einem Notfallbetrieb für einen modularen Multilevelkonverter

Die vorliegende Erfindung betrifft ein Verfahren und ein System zu einem Notfallbetrieb für einen modularen Multilevelkonverter, wobei der modulare Multilevelkonverter eine Zentralsteuerung und eine Mehrzahl an Batteriemodulen aufweist. Das jeweilige Batteriemodul wird durch die Zentralsteuerung zu jedem Schalttakt mit einem jeweiligen Schaltzustand versehen, durch welchen ein jeweiliger Energiespeicher mit einem jeweiligen Energiespeicher eines jeweilig benachbarten Batteriemoduls verschaltet wird. Der jeweilige Schaltzustand wird ausgewählt aus einer Gruppe mindestens umfassend eine serielle oder eine parallele oder eine Bypass-Verschaltung. Durch eine Modulüberwachung wird ein jeweilig fehlerhafter Energiespeicher an die Zentralsteuerung gemeldet. Für das jeweilige Batteriemodul mit fehlerhaftem Energiespeicher wird zu jedem weiteren Schalttakt ein Bypass-Schaltzustand (210, 220) festgesetzt. Bei Überschreiten eines Schwellwertes, welcher durch eine vorgegebene Anzahl der für einen Betrieb des modularen Multilevelkonverters tolerierbaren fehlerhaften Energiespeicher definiert wird, wird ein Notfallbetrieb veranlasst, welcher mindestens folgende Schritte umfasst:• Betriebszustand wechselt von „Betriebsmodus“ in einen „Reparaturmodus“;• Anzeige des Wechsels in „Reparaturmodus“ in Bediendisplay;• Beschränkung einer weiteren Betriebsdauer bis zu einem Reparaturbeginn.

Covering means for a component of an electrical drive system, and component provided therewith

A covering means is provided for a component of an electrical drive system having or consisting of a first metallic layer, wherein the first metallic layer is equipped to be vibration-damping.

Bioaktive peptide, die durch enzymatische hydrolyse aus den proteinen von eiweiss gewonnen werden